Lucid Diagnostics Inc. LUCD
0.41 USD 0.00 (+0.66%)
At closeNov 3, 2026, 7:46 PM EST
0.40 -0.01 -1.83%
After hours · Nov 3, 7:46 PM ET
0.3963 Day range 0.4343
0.303 52-week range 1.63
- YTD
- -62.48%
- 1 year
- -66.20%
- Market cap
- 78.10M
- Revenue (ttm)
- 4.19M
- EPS (ttm)
- -0.44
- Shares out
- 59.34M
- Forward P/E
- -1.12
- YTD return
- -62.48%
- 1-year return
- -66.20%
- Volume
- 1.61M
- Avg volume
- 4.90M
- Open
- 0.40
- Previous close
- 0.4063
- Day's range
- 0.3963 – 0.4343
- 52-week range
- 0.303 – 1.63
- Analysts
- Strong Buy
- Price target
- 3.50 (+755.7%)
- Earnings date
- Aug 12, 2024
YTD -0.7110 (-63.48%)
Key statistics
- Enterprise value
- 94.79M
- PEG ratio
- 0.00
- Price / sales
- 10.98
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 49.70%
- Free cash flow
- -39.47M
- Total cash
- 14.49M
- Total debt
- 13.07M
- Return on equity
- -1007.83%
- Short % of float
- 1.74%
- 50-day average
- 0.90474
- 200-day average
- 0.87091
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 3.50 +755.7% upside
Now 0.409
- Target (low)
- 2.00
- Target (mean)
- 3.50
- Target (high)
- 7.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.14667.
Financials — quick view
LUCD Revenue — quarterly 1.47M
LUCD Net income — quarterly -11.69M
LUCD EPS — quarterly -0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.16 | -0.20 | -0.04 | -25.00% |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.20 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.21 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 15, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 14, 2024 | Needham | reit | Buy | Buy |
| Sep 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- luciddx.com
News
PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes 
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study 
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on LUCD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKLOG LISHAN | Chief Executive Officer | Stock Award(Grant) | May 6, 2024 | 1,166,630 |
| GORDON MICHAEL ADAM | General Counsel | Stock Award(Grant) | May 6, 2024 | 400,000 |
| LAPIDUS STANLEY N | Director | Sale | Sep 25, 2023 | 101,592 |
| MCGRATH DENNIS M | Chief Financial Officer | Stock Award(Grant) | May 6, 2024 | 1,043,570 |
| O'NEIL SHAUN | President | Stock Award(Grant) | May 6, 2024 | 526,763 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Luminus Management, LLC | 1.94% | 1,152,915 | 893.62K | Sep 29, 2024 |
| Vanguard Group Inc | 0.95% | 560,915 | 434.76K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.36% | 213,540 | 165.51K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 0.21% | 126,362 | 97.94K | Sep 29, 2024 |
| Lido Advisors, LLC | 0.17% | 100,016 | 77.52K | Sep 29, 2024 |
| Levin Capital Strategies, LP | 0.11% | 66,528 | 51.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.62% | 366,924 | 284.40K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.33% | 193,991 | 150.36K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 101,556 | 78.72K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 56,571 | 43.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 23,997 | 18.60K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 12,873 | 9.98K | Oct 30, 2024 |